Tags

Type your tag names separated by a space and hit enter

[Low prevalence of anti-centromere antibodies in scleroderma in Morocco (about 272 cases)].
Ann Biol Clin (Paris) 2007 May-Jun; 65(3):291-7AB

Abstract

PURPOSE

assessment of autoantibodies prevalence during scleroderma within a Moroccan population by a retrospective survey.

MATERIAL AND METHODS

272 patient (220 cases of systemic sclerosis, 45 cases localised scleroderma and 7 cases of mixed connective tissue disease (MCTD)) underwent a screening for antinuclear antibodies (ANA) by indirect immunofluorescence (IFI) on Hep-2 cells, followed, in 127 cases, by anti-extractable nuclear antigen (ENA) antibodies identification using a double immunodiffusion (IDD) method.

RESULTS

sixty eight for percent of patients presenting with a systemic sclerosis had positive ANA whose identification revealed: 23 cases (15.3%) of anti-topoisomerase I, 8 cases (5.3%) of anti-centromere (ACA) and 5 cases (3.3%) of anti-U1-RNP antibodies. Out of the 8 cases of ACA, 3 corresponded to a CREST syndrome. Anti-topoisomerase I antibodies were observed in 2 of the 4 patients having an interstitial pulmonary syndrome. Anti-U1-RNP antibodies were present in 3/38 patients (7.8%) having a systemic sclerosis associated to arthritis. 4/45 patients (9%), presenting with a localised scleroderma, had positive ANA, of which 2 were ACA. All patients admitted for MCTD had anti-U1-RNP antibodies, coexisting with anti-Sm antibody in 2 cases.

CONCLUSION

the low prevalence of ACA observed in this survey, when compared to American, European and Japanese studies, is probably due to ethnic variation in frequency of ANA. Indeed, low rates or absence of ACA have been reported in south-African, Afro-American, Indian, and Thai studies. The IDD, method of reference for detecting of anti-ENA antibodies, identify a small fraction of anti-nucleolar aspects of scleroderma. Thus, other methods such as ELISA and/or immunoblotting are required to complete their identification.

Authors+Show Affiliations

Faculté de médecine, Marrakech, Morocco. brahimadmou@yahoo.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

fre

PubMed ID

17502303

Citation

Admou, B, et al. "[Low Prevalence of Anti-centromere Antibodies in Scleroderma in Morocco (about 272 Cases)]." Annales De Biologie Clinique, vol. 65, no. 3, 2007, pp. 291-7.
Admou B, Arji N, Seghrouchni F, et al. [Low prevalence of anti-centromere antibodies in scleroderma in Morocco (about 272 cases)]. Ann Biol Clin (Paris). 2007;65(3):291-7.
Admou, B., Arji, N., Seghrouchni, F., Missoum, H., El Fenniri, L., Amghar, S., & El Aouad, R. (2007). [Low prevalence of anti-centromere antibodies in scleroderma in Morocco (about 272 cases)]. Annales De Biologie Clinique, 65(3), pp. 291-7.
Admou B, et al. [Low Prevalence of Anti-centromere Antibodies in Scleroderma in Morocco (about 272 Cases)]. Ann Biol Clin (Paris). 2007;65(3):291-7. PubMed PMID: 17502303.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Low prevalence of anti-centromere antibodies in scleroderma in Morocco (about 272 cases)]. AU - Admou,B, AU - Arji,N, AU - Seghrouchni,F, AU - Missoum,H, AU - El Fenniri,L, AU - Amghar,S, AU - El Aouad,R, PY - 2006/08/07/received PY - 2007/01/29/accepted PY - 2007/5/16/pubmed PY - 2007/10/30/medline PY - 2007/5/16/entrez SP - 291 EP - 7 JF - Annales de biologie clinique JO - Ann. Biol. Clin. (Paris) VL - 65 IS - 3 N2 - PURPOSE: assessment of autoantibodies prevalence during scleroderma within a Moroccan population by a retrospective survey. MATERIAL AND METHODS: 272 patient (220 cases of systemic sclerosis, 45 cases localised scleroderma and 7 cases of mixed connective tissue disease (MCTD)) underwent a screening for antinuclear antibodies (ANA) by indirect immunofluorescence (IFI) on Hep-2 cells, followed, in 127 cases, by anti-extractable nuclear antigen (ENA) antibodies identification using a double immunodiffusion (IDD) method. RESULTS: sixty eight for percent of patients presenting with a systemic sclerosis had positive ANA whose identification revealed: 23 cases (15.3%) of anti-topoisomerase I, 8 cases (5.3%) of anti-centromere (ACA) and 5 cases (3.3%) of anti-U1-RNP antibodies. Out of the 8 cases of ACA, 3 corresponded to a CREST syndrome. Anti-topoisomerase I antibodies were observed in 2 of the 4 patients having an interstitial pulmonary syndrome. Anti-U1-RNP antibodies were present in 3/38 patients (7.8%) having a systemic sclerosis associated to arthritis. 4/45 patients (9%), presenting with a localised scleroderma, had positive ANA, of which 2 were ACA. All patients admitted for MCTD had anti-U1-RNP antibodies, coexisting with anti-Sm antibody in 2 cases. CONCLUSION: the low prevalence of ACA observed in this survey, when compared to American, European and Japanese studies, is probably due to ethnic variation in frequency of ANA. Indeed, low rates or absence of ACA have been reported in south-African, Afro-American, Indian, and Thai studies. The IDD, method of reference for detecting of anti-ENA antibodies, identify a small fraction of anti-nucleolar aspects of scleroderma. Thus, other methods such as ELISA and/or immunoblotting are required to complete their identification. SN - 0003-3898 UR - https://www.unboundmedicine.com/medline/citation/17502303/[Low_prevalence_of_anti_centromere_antibodies_in_scleroderma_in_Morocco__about_272_cases_]_ L2 - http://www.jle.com/medline.md?issn=0003-3898&vol=65&iss=3&page=291 DB - PRIME DP - Unbound Medicine ER -